Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155118 | 0.74 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12263416 | 0.65 | MAPT (0.32) | — | |
| SCHEMBL9534613 | 0.64 | — | — | |
| SCHEMBL12263412 | 0.62 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17206989 | 0.62 | CHRNB2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6736093 | 0.61 | SELL (0.37) | RAB9A | |
| SCHEMBL29923274 | 0.61 | HTR2A (0.32) | RAB9A | |
| SCHEMBL20590031 | 0.61 | — | — | |
| SCHEMBL8363106 | 0.61 | RAB9A (0.50) | RAB9A | |
| SCHEMBL13818128 | 0.60 | HTR2C (0.47) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996291-B1 | USE OF DIGITALIS-LIKE COMPOUNDS IN THE TREATMENT OF AFFECTIVE DISORDERS | YISSUM RES DEV CO (IL) | 2010-11-17 | — | — | EP | disclosed |
| EP-2156862-A1 | Use of digitalis-like compounds in the treatment of affective disorders | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2010-02-24 | — | — | EP | disclosed |
| US-20090209504-A1 | Use of Digitalis-Like Compounds in the Treatment of Affective Disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-08-20 | — | — | US | disclosed |
| US-20090209504-A1 | Use of Digitalis-Like Compounds in the Treatment of Affective Disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-08-20 | — | — | US | disclosed |
| WO-2007108002-A2 | USE OF DIGITALIS-LIKE COMPOUNDS IN THE TREATMENT OF AFFECTIVE DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209504-A1 | Use of Digitalis-Like Compounds in the Treatment of Affective Disorders | HTR1B, HTR2B, SLC18A2 | CHRM2 4208/4885CHRM4 3121/4885CHRM5 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.